Information for healthcare professionals

Overview

REMAP-CAP is a global Bayesian adaptive platform trial that evaluates multiple interventions for hospitalised patients with respiratory tract infection. One treatment that REMAP-CAP is evaluating are influenza antivirals, including oseltamivir, a neuraminidase inhibitor that prevents the replication of the influenza virus.

Oseltamivir is widely used for the treatment of critically ill patients with influenza based on evidence from less sick patients, however evidence from randomised clinical trials about its efficacy in the critically ill is lacking.

At a scheduled adaptive analysis, oseltamivir interventions in the platform’s Influenza Antiviral Domain met a predefined statistical threshold for inferiority among critically ill patients aged 12 years or older.

A pre-print of this manuscript can be found here. It has yet to be formally peer-reviewed.

Preliminary results from this domain of REMAP-CAP were recently presented at the Critical Care Reviews conference. A recording of this presentation can be found by clicking here. These presented results were preliminary results. The numbers in the manuscript have now been updated with the final results.

Should you have any further questions please email info@remapcap.org